Radiotherapy Strategies for Stage II Breast Cancer With Lymphovascular Invasion After Mastectomy.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: pathologically confirmed LVI who received radiotherapy (RT) between October 2017 and July 2020
I · Intervention 중재 / 시술
radiotherapy (RT) between October 2017 and July 2020
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
PMRT provides survival benefits for LVI-positive patients who achieve ypN0 status after NAC and is recommended. Larger studies are needed to validate these findings.
[BACKGROUND/AIM] Lymphovascular invasion (LVI) is a strong prognostic factor associated with poor survival outcomes in breast cancer.
- 표본수 (n) 273
- HR 0.359
APA
Gao S, Yu X, et al. (2026). Radiotherapy Strategies for Stage II Breast Cancer With Lymphovascular Invasion After Mastectomy.. Anticancer research, 46(2), 1037-1052. https://doi.org/10.21873/anticanres.18007
MLA
Gao S, et al.. "Radiotherapy Strategies for Stage II Breast Cancer With Lymphovascular Invasion After Mastectomy.." Anticancer research, vol. 46, no. 2, 2026, pp. 1037-1052.
PMID
41617430 ↗
Abstract 한글 요약
[BACKGROUND/AIM] Lymphovascular invasion (LVI) is a strong prognostic factor associated with poor survival outcomes in breast cancer. However, the clinical benefit of postmastectomy radiotherapy (PMRT) for early-stage disease remains uncertain. This study aimed to evaluate PMRT efficacy and related prognostic factors in real-world settings.
[PATIENTS AND METHODS] We retrospectively analyzed 322 postoperative breast cancer patients with pathologically confirmed LVI who received radiotherapy (RT) between October 2017 and July 2020. Patients were categorized into two groups: Group A (pT1-2N1M0, n=273), who underwent modified radical mastectomy (MRM) with or without adjuvant RT; and Group B [stage II, ypN0 after neoadjuvant chemotherapy (NAC) and surgery, with or without adjuvant RT, n=49]. Intergroup differences were assessed using the chi-squared test, and Kaplan-Meier analysis estimated local recurrence-free survival (LRFS), disease-free survival (DFS), overall survival (OS), and distant DFS (DDFS).
[RESULTS] Group A: Patients who received adjuvant RT had significantly improved 5-year LRFS (94.4% . 85.5%, HR=0.359, 95% CI=0.147-0.879; <0.05) and DFS (88.9% . 78.8%, HR=0.488, 95% CI=0.253-0.940; <0.05) compared to those without RT. No significant difference was observed in 5-year OS or DDFS. Subgroup analysis indicated a higher recurrence risk among patients with two to three positive lymph nodes or triple-negative tumors. Group B: Among patients who achieved ypN0 status, adjuvant RT significantly improved 5-year DFS (95.8% . 76.0%), OS (100.0% . 84.0%), and DDFS (100.0% . 80.0%) (<0.05), with no significant difference in LRFS.
[CONCLUSION] In stage II LVI-positive breast cancer patients, adjuvant RT improves local control and leads to an increase in DFS but not OS. PMRT provides survival benefits for LVI-positive patients who achieve ypN0 status after NAC and is recommended. Larger studies are needed to validate these findings.
[PATIENTS AND METHODS] We retrospectively analyzed 322 postoperative breast cancer patients with pathologically confirmed LVI who received radiotherapy (RT) between October 2017 and July 2020. Patients were categorized into two groups: Group A (pT1-2N1M0, n=273), who underwent modified radical mastectomy (MRM) with or without adjuvant RT; and Group B [stage II, ypN0 after neoadjuvant chemotherapy (NAC) and surgery, with or without adjuvant RT, n=49]. Intergroup differences were assessed using the chi-squared test, and Kaplan-Meier analysis estimated local recurrence-free survival (LRFS), disease-free survival (DFS), overall survival (OS), and distant DFS (DDFS).
[RESULTS] Group A: Patients who received adjuvant RT had significantly improved 5-year LRFS (94.4% . 85.5%, HR=0.359, 95% CI=0.147-0.879; <0.05) and DFS (88.9% . 78.8%, HR=0.488, 95% CI=0.253-0.940; <0.05) compared to those without RT. No significant difference was observed in 5-year OS or DDFS. Subgroup analysis indicated a higher recurrence risk among patients with two to three positive lymph nodes or triple-negative tumors. Group B: Among patients who achieved ypN0 status, adjuvant RT significantly improved 5-year DFS (95.8% . 76.0%), OS (100.0% . 84.0%), and DDFS (100.0% . 80.0%) (<0.05), with no significant difference in LRFS.
[CONCLUSION] In stage II LVI-positive breast cancer patients, adjuvant RT improves local control and leads to an increase in DFS but not OS. PMRT provides survival benefits for LVI-positive patients who achieve ypN0 status after NAC and is recommended. Larger studies are needed to validate these findings.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Correction of Sunken Upper Eyelid in Asian Blepharoplasty Based on Anatomical and Histological Study of Orbital Fat Fascia Flap.
- Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.
- Effect of Fuzheng Pill on Liver Cancer via the Mitochondrial Apoptosis Pathway.
- Mll5 haploinsufficiency attenuates microglial phagocytosis through dysregulated TREM2-SGK3-GSK3β signaling and recapitulates ASD-like behaviors in mice.
- A Retrospective Analysis of Primary Bone Marrow Lymphoma: Clinical Features and Prognostic Factors.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.